The Board of Pharmacy adopted Temporary Rule OAR 855-007-0088 related to Compliance with Oregon Health Authority’s COVID Rules, effective October 18.

Also in Oregon, the Board of Pharmacy has proposed to permanently adopt numerous rules outlined below. Note: written comments may be submitted via email to pharmacy.rulemaking@bop.oregon.gov before 4:30 p.m. on November 23.

• Division 007 – related to Compliance with OHA COVID Rules
• Division 007/041/045/065 – related to USP, Storage, Labeling, Repackaging 
• Division 010 – related to Board Administration & Policies
• Division 019/139 – related to Remote Dispensing Site Pharmacy
• Division 041/080 – related to Pseudoephedrine/Ephedrine
• Division 019/021 – related to Pain Management CE
• Division 020 – related to Pharmacist Prescriptive Authority – COVID mAb, PEP & PrEP
• Division 043 – related to SPDO/DPDO/CHC
• Division 060/110 – related to PDMP Fee Increase
• Division 006/041 – related to Telework, Remote Processing & TCVP

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy has posted the agenda for the October 27, 2021 CE Rules Advisory Committee meeting.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy will hold a meeting on October 13-15. The agenda has been posted including information for public participation by phone.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy issued a notice requesting stakeholder fiscal impact information related to proposed requirements for “Proper Storage of Drugs”, “Remote Dispensing Site Pharmacies” and “Telework”. Note: The board reminds pharmacies that some information they may want to provide may be proprietary, and any information provided to the Board of Pharmacy becomes a public record.  By October 6, please provide comments to pharmacy.rulemaking@bop.oregon.gov.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy filed a temporary rule effective September 1, 2021 through February 27, 2022, adding COVID-19 monoclonal antibody protocol to the Protocol Compendia based on the Public Health & Pharmacy Formulary Advisory Committee recommendation.

Also in Oregon, the Board of Pharmacy Rules Advisory Committee will meet via teleconference on September 23 to discuss technician rules.  Information to participate by phone is printed in the agenda.

Also in Oregon, the Public Health and Pharmacy Formulary Advisory Committee will meet on September 24.  Topics of interest include pseudoephedrine, PEP/PrEP and vaccines.  See agenda for details.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy announced a Technician Rules Advisory Committee meeting on August 25.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy will meet on August 11-12; meeting materials have been posted online.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Oregon Health Authority revised regulations under OAR 333-047 and -049 regarding requirements for health care persons, entities and other enrolled providers that receive, store, administer or transfer coronavirus (COVID-19) vaccines, including reporting the amounts of doses administered and that are in inventory to the immunization registry, also known as the immunization information system. The rule was effective July 12, 2021.

The Oregon Health Authority, Public Health Division, temporarily adopted regulations under OAR 333-047 to prohibit health care providers and vaccine sites from requiring parental consent for coronavirus (COVID-19) vaccination for minors age 15 to 17 years, and from asking for a Social Security number. The temporary rule also requires persons or entities administering state-supplied COVID-19 vaccines to have a designated site coordinator, post signs with the site coordinator’s contact information, provide information about when and where to get a second dose and provide a vaccine card as proof of vaccination. The rule, which replaces an earlier temporary rule on the same topic, is effective July 9, 2021, and expires November 22, 2021. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

Effective June 15, 2021, the Board of Pharmacy amended the following regulations: 

• OAR 855-007 to allow pharmacists at immunizing clinics to supervise as many state-licensed immunizing interns as they determine will maintain public health and safety during a declared public health emergency. The rule is response to the coronavirus (COVID-19) pandemic.  
• OAR 855-041 to remove the limit on epinephrine dispensed to an entity to allow maintenance of epinephrine at coronavirus (COVID-19) vaccination locations.  
• OAR 855-019, -021, -025 and -031 to incorporate cultural competency continuing education requirements for pharmacists, pharmacy technicians and pharmacy interns.  
• OAR 855-020 to update the statewide drug therapy management protocols in the formulary and protocol compendia.  

• OAR 855-001 and -041 to revise requirements for inspection of drug outlets, including performance by the Compliance Officer, and for pharmacy records.  
• OAR 855-110 to revise the late fee expiration dates for licensees and registrants.  
• OAR 855-080 to ensure clarity, transparency and promote patient safety related to controlled substances. 
• OAR 855-006 and repeals regulations under OAR 855-050 to remove outdated restrictions on retail drug sales and make a confirming change to incorporate the definition of “prescription drug.”  
• OAR 855-041 to clarify requirements for pharmacies related to Drug Take Back Programs.  

Also in Oregon, on June 15, 2021, Gov. Kate Brown (D) signed HB 2648, removing the existing prescription only requirement for purchases of pseudoephedrine (PSE) containing medications and instituting the National Precursor Log Exchange (NPLEx) in its place. As a result of this newly enacted law, Oregon becomes the 37th state to mandate the use of NPLEx, and no state will require a prescription for the purchase of a Food and Drug Administration (FDA) approved over-the-counter product containing PSE. NACDS acknowledges the efforts of CHPA to support this repeal over the last several years. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.